Tigecycline: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
'''''For patient information, click <u>[[Tigecycline (patient information)|here]]</u>'''''. | '''''For patient information, click <u>[[Tigecycline (patient information)|here]]</u>'''''. | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Overview== | ==Overview== | ||
Revision as of 04:04, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Tigecycline (INN) (IPA: Template:IPA) is anglycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence ofantibiotic resistance in bacteria such as Staphylococcus aureus.
Category
Glycopeptide
US Brand Names
TYGACIL®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages